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Abstract
Background: To investigate the frequency and relationship of the KRAS, BRAF and PIK3CA mutations and the loss of PTEN
expression in Chinese patients with colorectal cancer (CRC).
Methodology/Principal Findings: Genomic DNA was extracted from the formalin-fixed paraffin-embedded (FFPE) tissues of
69 patients with histologically confirmed CRC. Automated sequencing analysis was conducted to detect mutations in the
KRAS (codons 12, 13, and 14), BRAF (codon 600) and PIK3CA (codons 542, 545 and 1047). PTEN protein expression was
evaluated by immunohistochemistry on 3 mm FFPE tissue sections. Statistical analysis was carried out using SPSS 16.0
software. The frequency of KRAS, BRAF and PIK3CA mutations and loss of PTEN expression was 43.9% (25/57), 25.4% (15/59),
8.2% (5/61) and 47.8% (33/69), respectively. The most frequent mutation in KRAS, BRAF and PIK3CA was V14G (26.7% of all
mutations), V600E (40.0% of all mutations) and V600L (40.0% of all mutations), and H1047L (80.0% of all mutations),
respectivly. Six KRAS mutatant patients (24.0%) harbored BRAF mutations. BRAF and PIK3CA mutations were mutually
exclusive. No significant correlation was observed between the four biomarkers and patients’ characteristics.
Conclusions/Significance: BRAF mutation rate is much higher in this study than in other studies, and overlap a lot with KRAS
mutations. Besides, the specific types of KRAS and PIK3CA mutations in Chinese patients could be quite different from that
of patients in other countries. Further studies are warranted to examine their impact on prognosis and response to targeted
treatment.
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Introduction
Two monoclonal antibodies (MoAb) targeted at epidermal
growth factor receptor (EGFR), the chimeric IgG1 MoAb
cetuximab and the fully humanized IgG2 panitumumab, have
proven to be effective in combination with chemotherapy or as
single agent for treatment of metastatic colorectal cancer (mCRC)
[1,2,3]. However, the efficacy of MoAb is not consistent for every
patient; some patients experience dramatic response to MoAb,
whereas others show no response [4,5,6]. In order to facilitate
selection of mCRC patients who may benefit from anti-EGFR
MoAbs treatments, there is a clear need for identifying predictive
biomarkers that indicate likelihood of response amongst potential
recipients.
It has been reported that oncogenic activations of intracellular
signaling pathways downstream of EGFR, including the RAS-
RAF-MAPK and PI3K-PTEN-AKT signaling pathways, are
important mechanisms for generating resistance to anti-EGFR
MoAbs. In the RAS-RAF-MAPK pathway, active mutations of
KRAS or BRAF are not uncommon, as such mutations are present
in 35.0–45.0% and in 4.0–15.0% of mCRC patients respectively
[7]. In the PI3K-PTEN-AKT pathway, mutations of PI3KCA or
loss of PTEN expression are observed in 10.0–18.0% and 19.0–
42.0% of mCRC patients respectively [7]. Mutations of PIK3CA,
may coexist with either KRAS or BRAF within the same tumor [8],
but KRAS and BRAF mutations appear to be mutually exclusive
[7].
To date, KRAS mutations have been identified as a predictive
marker of resistance to anti-EGFR MoAbs in patients with
mCRC, and the use of anti-EGFR MoAbs is now restricted to
mCRC patients with wild-type KRAS [9]. However, the occur-
rence of KRAS mutations only accounts for approximately 30% to
40% of nonresponsive patients [10]. In patients with KRAS wild-
type tumors, it remains unclear why a large number of patients are
still not responsive to the treatment. More recently, other
oncogenic mutations, such as BRAF [11,12], PIK3CA mutations
[10] or loss of PTEN expression [12,13], are found likely to be
promising predictors for the resistance in mCRC patients with
wild-type KRAS.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36653Most of the studies that investigated the predictive value of
KRAS, BRAF, PIK3CA mutations and loss of PTEN expression
were performed in western countries. Little is known about the
relation of these biomarkers with the clinical outcomes of MoAb
treatment in Chinese patients with mCRC. We did not even know
the frequency of these biomarkers occurred in Chinese patients. In
this study, we investigated the status of KRAS, BRAF, PI3KCA
mutation and PTEN expression in primary tumor from 69
Chinese mCRC patients, to clarify the rate of mutations and to
detect the correlation between mutations and clinicopathological
factors.
Materials and Methods
Patients and tissue samples
The analysis was conducted in 69 patients with histologically
confirmed colorectal cancer (40 males and 29 females with a mean
age of 54 years) who underwent tumor resection at Nanfang
Hospital during the period of July 2010 to March 2011. Sixty-nine
primary tumor samples were collected from surgical specimens. All
of the collected samples are formalin-fixed paraffin-embedded
(FFPE) tissues. This study was approved by the Institutional Ethics
Committee of the Nanfang Hospital and was performed according
to the institutional Guidelines. Written consent was given by the
patients for their information to be stored in the hospital database
and used for research. In our study, written informed consent was
not obtained from the participants, because the study was
retrospective and our data was analyzed anonymously. A
summary of the demographic and clinicopathological data was
listed in Table 1. Patients who ever smoked at least one cigarette
per day for at least 6 months were categorized as smokers,
including current smokers and previous smokers. The rest of
patients were categorized as non-smokers. We considered patients
who have at least 3 drinks per week on average in the past two
years as drinkers, while the rest of patients were categorized as
non-drinker.
DNA extraction and mutational analysis of KRAS, BRAF
and PIK3CA
Two appropriate FFPE samples were selected from each
patient. For every sample, three 5–10 mm sections were prepared.
Genomic DNA was extracted by a standard SDS-proteinase K
procedure. After extraction, DNA was purified.
We searched for mutations in KRAS exon 2, BRAF exon 15 and
PIK3CA exons 9 and 20. KRAS exon 2 includes codons 12, 13 and
14, BRAF exon 15 includes codon 600, PIK3CA exon 9 includes
codons 542 and 545 and PIK3CA exon 20 includes codon 1047,
where the large majority of mutations occur in these genes [11].
Ten types of mutations in KRAS codons 12, 13 and 14 (G12C,
G12D, G12V, G12R, G12A, G12G, G13D, G13G, V14G and
V14A), 4 types of mutations in BRAF codon 600 (V600E, V600Q,
V600L and V600V), 4 types of mutations in PIK3CA codons 542
and 545 (E542K, E545K, E545G and E545A) and two types of
PIK3CA codon 1047 (H1047R and H1047L) were detected. The
nucleotide sequence corresponding to every exon was amplified
from extracted genomic DNA. Table 2 shows the list of primers
used for each exon. Conditions for the amplification of exon-
specific regions from genomic DNA by PCR have been described
in previous study [11]. PCR products were subjected to automated
sequencing by ABI PRISM 3730 (Applied Biosystems, Foster City,
CA, USA). All mutated cases were confirmed twice with
independent PCR reactions. New data was not generated in our
study. The results for mutation analyses are given in appendix S1
and S2 (Figures for sequencing results).
PTEN expression
PTEN protein expression was evaluated by immunohistochem-
istry on 3 mm FFPE tissue sections as reported in previous study
Table 1. Characteristics of 69 patients with metastatic
colorectal cancer.
Characteristics
Sex-No. (%)
Male 40(58.0)
Female 29 (42.0)
Missing 0(0.0)
Age
#65-No. (%) 57(82.6)
.65-No. (%) 12(17.4)
Missing-No. (%) 0(0)
Mean6SD-yr 54.0612.0
Range-yr 31.0–78.0
Drinking History-No. (%)
Yes 9(13.0)
No 58(84.1)
Missing 2(2.9)
Smoking History-No. (%)
Yes 16 (23.2)
No 51(73.9)
Missing 2(2.9)
Primary Tumor Site -No. (%)
Right colon 14(20.3)
Left colon 20(29.0)
Rectum 30(43.5)
Missing 5(7.2)
Tumor type-No. (%)
Mucinous 11(15.9)
Non-mucinous 56(81.2)
Missing 2(2.9)
Tumor Differentiation-No. (%)
G1 13(18.8)
G2 10(14.5)
G3 29(42.0)
G4 3(4.3)
Missing 14(20.3)
T-No. (%)q
T2 5(7.2)
T3 44(63.8)
T4 17(24.6)
Missing 3(4.3)
N-No. (%)q
N0 36(52.2)
N1 15(21.7)
N2 15(21.7)
Missing 3(4.3)
Legend.
qSixth edition of the AJCC/UICC TNM staging systems was applied.
doi:10.1371/journal.pone.0036653.t001
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was applied at 1: 50 dilution. Each run included appropriate
positive and negative control slides. A semi-quantitative score was
given to PTEN staining of tumor tissue by two independent
pathologists without knowledge of clinical data or results of
molecular analyses: negative(2), no staining at all; weak(+), weak
staining regardless of positive cell percentages or moderate staining
of #30% of cells; moderate (++), moderate staining of .30% of
cells or strong staining of #50% of cells; strong (+++), strong
staining of .50% of cells. Tumors with PTEN scores of 2 , + or
++ were considered to have PTEN loss. The figures for
immunohistochemical analysis are given in appendix S3.
Statistical analysis
Statistical analysis was conducted using SPSS 16.0 (SPSS, Inc.,
Chicago, IL). The x
2 test and Fisher’s exact test were used to
compare the proportion of KRAS, BRAF PIK3CA mutations and
loss of PTEN expression among different clinicopathologic groups.
To investigate the effects of covariates on gene mutations, multiple
logistic regression analysis using a forward stepwise (likelihood
ratio) method was done with odds ratio (OR) calculated. Initial
testing included age, gender, smoking history, drinking history,
tumor site and differentiation. Only variables showing statistically
significant association with gene mutations were subjected to final
regression analysis. The two-sided significance level was set at
P,0.05.
Results
KRAS mutation
KRAS mutational status was tested in 57 tumor tissues, of which
25 (43.9%) harbored at least one mutation at codons 12, 13 or 14.
The spectrum of these mutations was summarized in Table 3.
Eighteen (31.6%) tissues had a mutation at codon 12, 4 (7.0%) at
codon 13 and 8 (14.0%) at codon 14. The most frequent mutation
was V14G, which represented 26.7% of all mutations, followed by
G12D (20.0% of all mutations). Five tissues had concomitant
mutations at two codons (Appendix 1). We did not find any
significant association between KRAS mutations and patients’
characteristics by univariate analysis (Table 4) and multivariate
analysis (data not shown).
BRAF mutation
We detected BRAF codon 600 mutations in 15 (25.4%) out of 59
tumor tissues. The most frequent mutation was V600E (40.0% of
all mutations) and V600L (40.0% of all mutations) (Table 3). BRAF
and KRAS mutations were not mutually exclusive, with 24.0%
KRAS mutated patients and 29.0% wild-type KRAS patients
harboring BRAF mutations (Figure 1). No significant association
between KRAS mutations and patients’ characteristics was found
by univariate analysis (Table 4) and multivariate analysis (data not
shown).
PIK3CA mutation
The status of PIK3CA mutations was analyzed in 61 tumor
tissues with 5 positive results, giving a total mutation rate of 8.2%.
PIK3CA Exon9 mutation was seen in only one (1.7%) out of 58
tumor tissues tested (Table 3). By contrast, PIK3CA Exon20
mutations were identified in 4 out of 57 tumor tissues (7.0%), all
being H1047L (Table 3). KRAS and PIK3CA mutations were not
mutually exclusive (Figure 1). Three (12.0%) KRAS mutated
patients had PIK3CA mutations, all located in Exon20, whereas
two (6.3%) KRAS wild-type patients harbored PIK3CA mutations,
one in Exon9 and the other in Exon20. Of note, BRAF and
Table 2. The Primers used in PCR amplification and
sequencing.
KRAS-Exon2-Forward GGTGGAGTATTTGATAGTGTATTAACC
KRAS-Exon2-Reverse AGAATGGTCCTGCACCAGTAA
BRAF-Exon15-Forward TGCTTGCTCTGATAGGAAAATG
BRAF-Exon15-Reverse AGCATCTCAGGGCCAAAAAT
PIK3CA-Exon9-Forward GGGAAAAATATGACAAAGAAAGC
PIK3CA-Exon9-Reverse CTGAGATCAGCCAAATTCAGTT
PIK3CA-Exon20-Forward CTCAATGATGCTTGGCTCTG
PIK3CA-Exon20-Reverse TGGAATCCAGAGTGAGCTTTC
doi:10.1371/journal.pone.0036653.t002
Table 3. The frequency of KRAS, BRAF and PIK3CA mutations
according to different patterns.
Patterns of mutations No. of patients (%)
KRAS Exon2 (codon 12)
G12C 1(1.8)
G12D 6(10.5)
G12V 4(7.0)
G12R 1(1.8)
G12A 3(5.3)
G12G 3(5.3)
Wild-type 39(68.4)
KRAS Exon2 (codon 13)
G13D 1(1.8)
G13G 3(5.3)
Wild-type 53(93.0)
KRAS Exon2 (codon 14)
V14G 8(14.0)
V14A 0(0.0)
Wild-type 49(86.0)
BRAF Exon15 (codon 600)
V600E 6(10.2)
V600Q 2(3.4)
V600L 6(10.2)
V600V 1(1.70)
Wild-type 44(74.6)
PIK3CA Exon9 (codons 542 and 545)
E542K 0(0.0)
E545K 0(0.0)
E545G 1(1.7)
E545A 0(0.0)
Wild-type 57(98.3)
PIK3CA Exon20 (codon 1047)
H1047R 0(0.0)
H1047L 4(7.0)
Wild-type 53(93.0)
doi:10.1371/journal.pone.0036653.t003
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patients. No significant association between PIK3CA mutations
and patients’ characteristics was found by univariate analysis
(Table 4) and multivariate analysis (data not shown).
Loss of PTEN expression
We tested the PTEN expression in 69 tumor tissues. Loss of
PTEN expression was detected in 33 of them (47.8%), and was not
mutually exclusive with KRAS, BRAF or PIK3CA mutations
(Figure 1). Fourteen (56.0%) KRAS mutated patients had loss of
PTEN expression (Figure 1). We did not detect any statistically
significant association between PTEN expression and patients’
characteristics by univariate analysis (Table 4) and multivariate
analysis (data not shown).
Discussion
In this study, we detected various mutations of the KRAS,
BRAF and PIK3CA genes as well as the loss of PTEN expression
in 69 Chinese CRC patients. In addition, we also tried to correlate
the mutations with some clinical and pathological features. Some
previous studies have investigated the relationship between these
molecular events and various clinicopathological characteristics.
The results were however inconsistent. For example, Sartore-
Bianchi et al found that KRAS mutations were significantly more in
women than in men, while PIK3CA mutations and loss of PTEN
were not significantly associated with sex, age or site of tumor [14].
In contrast, Barault et al and Benvenuti et al found that PIK3CA
and BRAF mutations, but not mutations of KRAS, occur at a higher
frequency in women than men [10]. In Chinese CRC patients,
Shen et al found that gender was the only factor that showed an
obvious relationship with KRAS mutations (female 44.7% vs male
Table 4. Association of KRAS, BRAF and PIK3CA mutations and loss of PTEN expression with clinical and pathologic characteristics.
Variables KRAS BRAF PIK3CA PTEN expression
Mutations/Total
number (%) P
Mutations/Total
number (%) P
Mutations/Total
number (%) P
Loss/Total
number (%) P
Sex
Male 13/33(39.4) 0.426 11/34(32.4) 0.154 3/35(8.6) 1.000 17/40(42.5) 0.298
Female 12/24(50.0) 4/25(16.0) 2/26(7.7) 16/29(55.2)
Age
,65 22/46(47.8) 0.370 12/48(25.0) 1.000 4/49(8.2) 1.000 28/57(49.1) 0.638
§65 3/11(27.3) 3/11(27.3) 1/12(8.3) 5/12(41.7)
Drinking History
Yes 5/8(62.5) 0.436 3/9(33.3) 0.807 0/9(0.0) 1.000 3/9(33.3) 0.504
No 19/47(40.4) 11/48(22.9) 5/58(8.6) 30/58(51.7)
Smoking History
Yes 8/15(53.3) 0.375 4/16(25.0) 1.000 1/16(6.3) 1.000 6/16(37.5) 0.281
No 16/40(40.0) 10/41(24.4) 4/51(7.8) 27/51(52.9)
Primary Tumor Site
Right colon 5/11(45.5) 0.746 2/11(18.2) 0.701 1/14(7.1) 0.807 7/14(50.0) 0.321
Left colon 5/14(35.7) 5/16(31.3) 1/20(5.0) 7/20(35.0)
Rectum 13/27(48.1) 6/27(22.2) 3/30(10.0) 17/30(56.7)
Mucinous
Yes 6/10(60.0) 0.423 2/9(22.2) 1.000 1/11(9.1) 1.000 6/11(54.5) 0.701
No 18/45(40.0) 12/48(25.0) 4/56(7.1) 27/56(48.2)
Tumor Differentiation
G1 4/11(36.4) 0.990 2/12(16.7) 0.631 2/13(15.4) 0.514 5/13(38.5) 0.725
G2 3/7(42.9) 3/7(42.9) 0/10(0.0) 5/10(50.0)
G3 9/23(39.1) 6/25(24.0) 2/29(6.9) 16/29(55.2)
G4 1/3(33.3) 1/3(33.3) 0/3(0.0) 1/3(33.3)
T Stages
T2 2/5(40.0) 0.883 1/5(20.0) 0.886 0/5(0.0) 0.680 3/5 (60.0) 0.879
T3 17/37(45.9) 10/37(27.0) 4/38(10.5) 22/44(50.0)
T4 5/13(38.5) 3/14(21.4) 1/16(6.3) 8/17(47.1)
N Stages
N0 14/30(46.7) 0.553 10/30(33.3) 0.290 2/32(6.3) 0.143 19/36(52.8) 0.885
N1 6/12(50.0) 2/11(18.2) 0/12(0.0) 7/15(46.7)
N2 4/13(30.8) 2/15(13.3) 3/15(20.0) 7/15(46.7)
doi:10.1371/journal.pone.0036653.t004
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mutations in females and in non-smokers, and KRAS and BRAF
mutations were significantly associated with the proximal location
of cancer [16]. However, in the study of Li et al, BRAF mutation
did not correlate with age, gender, histological type or Dukes’
staging, but co-existent KRAS and PIK3CA mutations were more
likely to develop into liver metastasis [17].
In the present study, we did not find any significant correlations
between these molecular events and various clinicopathological
features (Table 4), which may be partly attributable to the
relatively small sample size. We observed some potential
tendencies. For example, KRAS mutations and loss of PTEN
seemed to be higher in female than in male patients. In addition,
KRAS, BRAF and PIK3CA mutations appeared to be more frequent
in those with a drinking or smoking history. However, larger
studies are needed to draw a firm conclusion on these issues.
KRAS gene encodes a 21 kDa RAS protein, which is a member
of the GTPases family involved in signal transduction processes.
Mutations in the KRAS can constitutively activate the protein in
signaling by eliminating the GTPase activity [15]. It has been
established that KRAS mutations are predictive biomarker for the
resistance to anti-EGFR monoclonal antibodies (MoAbs) treat-
ment in terms of response rate, progression-free survival and
overall survival. According to previous reports, the KRAS mutation
rate of CRC patients varies from 20.0% to 50.0%, mostly about
35.0%–45.0% [10,15]. In this study, 43.9% had a mutant KRAS
genotype, which means that, if KRAS mutational status testing is
applied to select candidates for anti-EGFR MoAbs treatment, the
proportion of Chinese CRC patients that would be excluded is
similar to that of other countries.
However, it should be noted that in this study, 14.0% of the
patients had codon 14 mutations (V14G). Among the few studies
that have taken interest in codon 14, a large series from US
showed that codon 14 mutations (V14I) occurred in only 0.1% of
the CRC patients [18]. And it is unknown whether these variants
are of specific pathogenicity [18]. Thus, it would be interesting to
see whether our results are reproducible in future Chinese patients
with mCRC. More importantly, further studies are warranted to
investigate the impact of codon 14 mutations on patients’
prognosis and response to anti-EGFR MoAbs. If these mutations
do not confer resistance to the treatment, then more Chinese
mCRC patients may benefit from anti-EGFR MoAbs.
In previous reports from western populations, G12D transitions
were the most frequently found type of KRAS codon 12 mutations,
followed by G12V, G12C, G12S and G12A [18,19]. However, in
our study, the corresponding order is G12D, G12V, G12A, G12G
and G12C, among which G12G was rarely seen in other studies.
As for codon 13 mutations, the majority of them were G13D,
followed by G13C and G13R in western populations [18,19]. In
the present study, only G13G, a newly found variant, and G13D
were detected. These data suggests that there may be racial
difference in the patterns of KRAS mutations. It has been reported
that the use of cetuximab was associated with longer overall and
progression-free survival among patients with chemotherapy-
refractory colorectal cancer with G13D-mutated tumors than
patients with other KRAS-mutated tumors [20]. Whether some of
the rarely seen or new mutations found in our study are also
associated with better treatment outcome remains unknown and
deserves further investigation.
Similar to KRAS gene, BRAF also encodes proteins that act in
the RAS-RAF-MAPK signaling pathway. Previous studies, both
Western and Chinese, reported that BRAF mutations were
detected in 5.0%–10.0% of CRC patients. Surprisingly, our study
demonstrated a quite high mutation rate, 25.4%, for BRAF.A
possible explanation is that most studies of BRAF mutation were
focused on V600E only [21], whereas our study analyzed four
types of mutations, i.e. V600E, V600Q, V600L and V600V.
However, even in De Roock’s study that detected D594G, V600E,
V600M and K601E, the mutation rate was only 10.9% [22].
Therefore, the high mutation rate in our study may be due to
other reasons, such as racial difference and environmental factors.
There is yet no consensus on the predictive role of BRAF mutations
in the anti-EGFR MoAbs treatment of mCRC. Some found that
V600E mutation was associated with worse outcome in metastatic
CRC patients treated with anti-EGFR MoAbs [23]. Others
suggested that this mutation was just a general prognostic factor
rather than a predictive factor specific to anti-EGFR monoclonal
antibodies, because its relationship with poor prognosis is
independent from the given treatment [24]. Mutations of KRAS
and BRAF genes are frequently found to be mutually exclusive in
colorectal cancer, both in Western and Chinese patients [25,26].
Thus, in general, with a KRAS mutation rate of 40.0% and a BRAF
mutation rate of 10.0%, one sixth or 16.7% of the KRAS wild-type
patients harbored BRAF mutations. Of note, BRAF mutations
overlap a lot with KRAS mutations in this study, with 29.0% of
wild-type KRAS patients harboring BRAF mutations. If BRAF
mutations were used to further select wild-type KRAS patients for
anti-EGFR MoAbs treatment, then significantly more Chinese
mCRC patients can be excluded.
The PIK3CA gene encodes the p110 catalytic subunit of PI3K
that regulates the pathways [27]. In agreement with previous
studies, we found that the mutation rate for PIK3CA is 8.7%, and
PIK3CA mutations are coexistent with KRAS mutations [10,23,28].
Besides, we observed more mutations at exon 20 than at exon 9,
which is consistent with studies of Chinese patients [29,30] but
quite different from the results from Western populations. This is
very important, because exon 9 and exon 20 mutations differ
greatly in affecting the response to anti-EGFR MoAbs. Our
previous systematic review found that PIK3CA exon 20 mutations
was associated with a lower response rate, shorter progression-free
survival and overall survival and thus may be a potential
biomarker for resistance to anti-EGFR MoAbs in KRAS wild-type
mCRC, whereas PIK3CA exon 9 mutations seemed to have no
such role [31]. Therefore, by testing PIK3CA mutation status, more
Chinese mCRC patients can be prevented from receiving anti-
EGFR MoAbs to which they are resistant.
Figure 1. The interrelationship between four biomarkers.
doi:10.1371/journal.pone.0036653.g001
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tumors gathered from seven European countries, De Roock found
that the E542K, E545K and Q546K mutations at exon 9
accounted for 15.6%, 26.8% and 4.2% of all the PIK3CA
mutations, while the H1047R and H1047L mutations at exon
20 accounted for 20.5% and 3.8% of all the mutations [22]. In the
present study, however, the most frequent type of mutations we
detected is H1047L, not the abovementioned hotspots, such as
E542K, E545K or H1047R. This indicates that there may be
large variations across different races. Interestingly, we found that
every patient that undertaken PIK3CA mutation analysis harbored
E542K and E545K mutations. We deemed these as ‘‘false
positive’’ results, which has been reported by others [32].
The loss of PTEN expression, which was reported to occur in
19.0%–42.0% of Western and 30.0%–64.0% of Chinese CRC
tumors [13,33,34,35,36,37], induces an increase in PIP-3 concen-
tration and PIK3CA pathway activation [23]. We detected the loss
of PTEN expression in 47.8% of the patients, consistent with
previous studies. Loss of PTEN expression has been reported to
confer tumor resistance to anti-EGFR MoAbs [38]. However,
since this PTEN loss can coexist with PIK3CA mutations, as shown
by the present and other studies, it is often difficult to differentiate
the contribution of loss of PTEN from that of PIK3CA mutations to
the lack of response [28].
The strength of this study is the comprehensive analysis of four
biomarkers in Chinese mCRC patients. However, the samples size
is relatively small, rendering some of our findings inconclusive.
Furthermore, we did not collect the data on treatment and clinical
outcomes, which will be addressed in our future studies.
In summary, this study adds to the evidence that KRAS and
PIK3CA mutations and the loss of PTEN expression in Chinese
mCRC patients occur at a comparable level to that of Western
patients. However, BRAF mutation rate is much higher in this
study than in previous studies. In addition, the specific types of
KRAS and PIK3CA mutations in Chinese population could be quite
different from that of patients in other countries, especially
considering the relatively high frequency of KRAS codon 14
mutations and PIK3CA exon 20 mutations. These findings have
important implications for the personalized treatment of Chinese
mCRC patients. Further studies are warranted to examine the
impact of some types of KRAS, BRAF and PIK3CA mutations on
prognosis and response to targeted treatment.
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